TrialThe Lancet. Oncology2017

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

José Baselga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.